cadazolid: for treatment of Clostridium difficile infections; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44242317 |
| CHEMBL ID | 3707376 |
| SCHEMBL ID | 541618 |
| MeSH ID | M000598150 |
| Synonym |
|---|
| 1025097-10-2 |
| act-179811 |
| unii-2oea2un10y |
| cadazolid [usan:inn] |
| cadazolid |
| 1-cyclopropyl-6-fluoro-7-(4-((2-fluoro-4-((r)-5-hydroxymethyl-2-oxooxazolidin-3-yl)phenoxy)methyl)-4-hydroxypiperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| 2oea2un10y , |
| SCHEMBL541618 |
| cadazolid [who-dd] |
| 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-7-(4-((2-fluoro-4-((5r)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)-4-hydroxy-1-piperidinyl)-1,4-dihydro-4-oxo- |
| cadazolid [usan] |
| cadazolid [inn] |
| CHEMBL3707376 |
| DTXSID10145234 |
| 1-cyclopropyl-6-fluoro-7-[4-[2-fluoro-4-[5(r )-(hydroxymethyl)-2-oxooxazolidin-3-yl]phenoxymethyl]-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;1-cyclopropyl-6-fluoro-7-[4-[2-fluoro-4-[5(r )-(hydroxymethyl)-2-oxooxazolidin-3-yl]ph |
| CS-6972 |
| HY-100436 |
| cadazolid (act-179811) |
| DB11847 |
| (r)-1-cyclopropyl-6-fluoro-7-(4-((2-fluoro-4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenoxy)methyl)-4-hydroxypiperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| BCP20623 |
| EX-A1438 |
| D11207 |
| cadazolid (usan/inn) |
| Q15408418 |
| JJH , |
| 1-cyclopropyl-6-fluoro-7-[4-[[2-fluoro-4-[(5r)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]-4-hydroxypiperidin-1-yl]-4-oxoquinoline-3-carboxylic acid |
| gtpl10767 |
| act179811 |
| A900061 |
| MS-30472 |
| AC-35473 |
| AKOS040757860 |
Cadazolid is a new antibiotic currently in late-stage clinical studies for the treatment of CDI. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile infection.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cadazolid had a lower recurrence rate than vancomycin (pooled OR = 0.71; 95% CI = 0.52 to 0.98; p=0.04; I2 = 13 %)." | ( Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis. Albert, E; Ali, N; Muhammad, A; Rawish, F; Sabih, R; Simcha, W, 2020) | 2.72 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cadazolid effectively treated simulated CDI in a gut model, with limited impact on the enumerated gut microflora and no signs of recurrence or emergence of resistance within the experimental timeframe." | ( In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. Athanasiou, A; Baines, SD; Chilton, CH; Crowther, GS; Freeman, J; Locher, HH; Todhunter, SL; Wilcox, MH, 2014) | 1.44 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The most common adverse event was headache, with no observed relationship between dose or treatment duration and adverse events." | ( Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. Baldoni, D; Dingemanse, J; Gutierrez, M; Timmer, W, 2014) | 1.85 |
Cadazolid and vancomycin were evaluated to treat simulated CDI. Each dosage of cadazolid resulted in a lower recurrence rate than with van comycin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the efficacy of two cadazolid dosing regimens (250 versus 750 mg/L twice daily for 7 days) to treat simulated CDI." | ( In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. Athanasiou, A; Baines, SD; Chilton, CH; Crowther, GS; Freeman, J; Locher, HH; Todhunter, SL; Wilcox, MH, 2014) | 1 |
| " Each dosage of cadazolid resulted in a lower recurrence rate than with vancomycin (18." | ( Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection. Buitrago, M; Charef, P; Cornely, OA; Gerding, DN; Kracker, H; Louie, T; Nord, CE; Talbot, GH; Wilcox, M, 2015) | 0.99 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (93.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (18.75%) | 5.53% |
| Reviews | 5 (31.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||